Platelet Disease

Xemilofiban is an orally active glycoprotein IIb/IIIa blocking agent. Xemilofiban inhibits platelet aggregation. Xemilofiban reduces the incidence of thrombosis.

SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation.

PDI-IN-2 is a highly selective PDI inhibitor. PDI-IN-2 has an IC₅₀ of 0.63-4.01 μM against human PDI, and exhibits higher targeting specificity compared with ERp57 and ERp72. PDI-IN-2 inhibits platelet aggregation induced by U46619, collagen and tumor cells, and also blocks platelet-promoted tumor cell proliferation as well as the growth of multiple myeloma cells. PDI-IN-2 serves as an important tool reagent for research on multiple myeloma and associated thrombosis.

Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.

Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.

Pirlindole mesylate is an orally active, selective and reversible MAO-A inhibitor with an IC₅₀ value of 250 nM. Pirlindole mesylate inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole mesylate inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole mesylate shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole mesylate can be used in research related to depression and enterovirus infections.

F050 is an orally active intracellular platelet calcium ([Ca²⁺]i) inhibitor. F050 inhibits thrombin-induced elevation of intracellular calcium in platelets. F050 inhibits platelet aggregation induced by CaCl₂, arachidonic acid, collagen, adenosine diphosphate (ADP), and thrombin across multiple species, and reduces thrombus formation in an extracorporeal circulation thrombosis model in guinea pigs. F050 also inhibits hypotonic NaCl-induced erythrocyte hemolysis and is used in research on thrombotic diseases.

Frunexian (EP-7041) hydrochloride is a small-molecule activated factor XI (FXIa) inhibitor. Frunexian hydrochloride has the characteristics of rapid onset and offset of action, a short half-life, dose-dependent prolongation of activated partial thromboplastin time, and an extremely low risk of bleeding. Frunexian hydrochloride exhibits good safety and tolerability and can be used in research related to thrombocytopenia, thromboembolism, thromboembolic diseases, and COVID-19.

Pizotifen (Standard) (Pizotyline (Standard)) is the analytical standard of Pizotifen (HY-B0115). This product is intended for research and analytical applications. Pizotifen (Pizotyline) is a 5-HT₂ receptor antagonist. Pizotifen inhibits the Wnt/β-catenin-EMT signaling pathway and induces mitochondria-mediated Apoptosis. Pizotifen causes transient ERK1/2 phosphorylation and restores ATP. Pizotifen blocks Serotonin (HY-B1473A)-mediated platelet activation, inhibits Serotonin-enhanced ADP-induced platelet aggregation, and prolongs carotid artery occlusion and tail bleeding time. Pizotifen exhibits anticancer activity against gastric cancer and colon cancer. Pizotifen exerts neuroprotective effects in the striatum of R6/2 mice. Pizotifen can be used for research on gastric cancer, colon cancer, Huntington's disease, metastasis, and thromboembolic diseases.

Ethaverine hydrobromide is a Papaverine derivative and vasodilator. Ethaverine hydrobromide inhibits Phosphodiesterase, Tyrosine hydroxylase, and MAO-B. Ethaverine hydrobromide blocks L-type Ca²⁺ channels, reduces intracellular Ca²⁺ levels, inhibits platelet adhesion and aggregation, regulates cardiac conduction and heart rate, and increases peripheral and cerebral blood flow. Ethaverine hydrobromide alters cochlear microcirculation, intracochlear Po₂, CM potential, and EP in guinea pigs, and induces transient hypotension. Ethaverine hydrobromide is used in the research of peripheral vascular diseases.

Bepristat 1a is a reversible, selective protein disulfide isomerase (PDI) inhibitor with an IC₅₀ of 0.7 μM. Bepristat 1a inhibits platelet aggregation in laser-injured mouse arterioles. Bepristat 1a is applicable for research related to thrombosis.

Pirlindole hydrochloride is an orally active, selective and reversible MAO-A inhibitor with an IC₅₀ value of 250 nM. Pirlindole hydrochloride inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole hydrochloride inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole hydrochloride shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole hydrochloride can be used in research related to depression and enterovirus infections.

4,5-Diphenyl-1,2,3-thiadiazole is a platelet aggregation inhibitor with an IC₅₀ of 3.2 μg/mL against collagen-induced platelet aggregation. 4,5-Diphenyl-1,2,3-thiadiazole can be used in thrombosis-related studies.

Pirlindole lactate is an orally active, selective and reversible MAO-A inhibitor with an IC₅₀ value of 250 nM. Pirlindole lactate inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole lactate inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole lactate shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole lactate can be used in research related to depression and enterovirus infections.

Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC₅₀ of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na⁺/K⁺-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis.

Pirlindole (Standard) is the analytical standard of Pirlindole (HY-100679). This product is intended for research and analytical applications. Pirlindole is an orally active, selective and reversible MAO-A inhibitor with an IC₅₀ value of 250 nM. Pirlindole inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole can be used in research related to depression and enterovirus infections.

Anemarrhenasaponin Ia is a steroidal saponin that can be isolated from the rhizomes of Anemarrhena asphodeloides Bunge. Anemarrhenasaponin Ia inhibits platelet aggregation. Anemarrhenasaponin Ia induces mild concentration-dependent hemolysis. Anemarrhenasaponin Ia inhibits fMLP- and AA-induced superoxide anion production, while enhancing PMA-induced superoxide anion production. Anemarrhenasaponin Ia can be used in studies related to thrombosis.

Pirlindole-d₄ is the d₄-labeled Pirlindole (HY-100679). Pirlindole is an orally active, selective and reversible MAO-A inhibitor with an IC₅₀ value of 250 nM. Pirlindole inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole can be used in research related to depression and enterovirus infections.